Biovica International AB (OSTO:BIOVIC B) Total Liabilities : kr22.45 Mil (As of Jan. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Biovica International AB Total Liabilities?

Biovica International AB's Total Liabilities for the quarter that ended in Jan. 2025 was kr22.45 Mil.

Biovica International AB's quarterly Total Liabilities declined from Jul. 2024 (kr24.58 Mil) to Oct. 2024 (kr21.54 Mil) but then increased from Oct. 2024 (kr21.54 Mil) to Jan. 2025 (kr22.45 Mil).

Biovica International AB's annual Total Liabilities increased from Apr. 2022 (kr27.54 Mil) to Apr. 2023 (kr33.65 Mil) and increased from Apr. 2023 (kr33.65 Mil) to Apr. 2024 (kr34.77 Mil).

Biovica International AB Total Liabilities Historical Data

The historical data trend for Biovica International AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biovica International AB Total Liabilities Chart

Biovica International AB Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Total Liabilities

Get a 7-Day Free Trial

12.04

9.99

27.54

33.65

34.77

Biovica International AB Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Total Liabilities	Get a 7-Day Free Trial															22.29	34.77	24.58	21.54	22.45

Biovica International AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Biovica International AB's Total Liabilities for the fiscal year that ended in Apr. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	28.291	+	(4.296	+	2.181
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	34.77

Total Liabilities	=	Total Assets (A: Apr. 2024 )	-	Total Equity (A: Apr. 2024 )
	=	131.408	-	96.64
	=	34.77

Biovica International AB's Total Liabilities for the quarter that ended in Jan. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	18.171	+	(2.473	+	1.803
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	22.45

Total Liabilities	=	Total Assets (Q: Jan. 2025 )	-	Total Equity (Q: Jan. 2025 )
	=	86.905	-	64.458
	=	22.45

Biovica International AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Biovica International AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biovica International AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biovica International AB (OSTO:BIOVIC B) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Dag Hammarskjolds vag 54B, Uppsala Science Park, Uppsala, SWE, 752 37

Website

https://www.biovica.com

Biovica International AB is a biotech company. The company develops and commercializes blood-based diagnostic tests with biomarkers that improve the monitoring and evaluation of modern cancer treatments. The company promotes healthcare through collaboration with cancer institutes and pharmaceutical companies. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Biovica International AB Headlines

No Headlines